Literature DB >> 1689774

Manifestations and treatment of human parvovirus B19 infection in immunocompromised patients.

W C Koch1, G Massey, C E Russell, S P Adler.   

Abstract

We diagnosed infections from human parvovirus B19 in three patients by using dot-blot hybridization and a polymerase chain reaction to detect B19 DNA and using an enzyme immunoassay to detect IgG and IgM to B19. For 5 months a 5-year-old boy with acute lymphoblastic leukemia in remission had anemia without reticulocytes or bone marrow erythrocyte precursors. His serum lacked IgG and IgM to B19 but contained B19 DNA. He received gamma globulin intravenously (0.4 gm/kg/day for 5 days); his viremia promptly cleared and reticulocytosis developed. A 14-year-old boy with acute lymphoblastic leukemia in remission had fever, rash, neutropenia (less than 300 leukocytes/mm3), and a hemophagocytic syndrome lasting 3 weeks. His serum contained IgM to B19 and B19 DNA. Without therapy, IgG to B19 developed; although low levels of B19 DNA persisted, the leukocyte count returned to normal. In a 19-year-old patient with systemic lupus erythematosus and hemolytic anemia, an aplastic crisis lasted 2 weeks. Her serum lacked IgG and IgM to B19 but contained B19 DNA. Without therapy, IgG and IgM to B19 appeared, viremia diminished, and reticulocytosis occurred. These patients illustrate the varied manifestations of chronic B19 infections, the importance of DNA detection for diagnosis, and the possible efficacy of gamma globulin therapy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1689774     DOI: 10.1016/s0022-3476(05)82820-3

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  14 in total

Review 1.  Pathogenesis of human parvovirus B19 in rheumatic disease.

Authors:  J R Kerr
Journal:  Ann Rheum Dis       Date:  2000-09       Impact factor: 19.103

2.  Acute parvovirus B19 infection mimicking myelodysplastic syndrome of the bone marrow.

Authors:  H Baurmann; T F Schwarz; J Oertel; S Serke; M Roggendorf; D Huhn
Journal:  Ann Hematol       Date:  1992-01       Impact factor: 3.673

3.  Increased risk of parvovirus B19 infection in young adult cancer patients receiving multiple courses of chemotherapy.

Authors:  Sung-Hsin Kuo; Liang-In Lin; Chee-Jen Chang; Yun-Ru Liu; Kuo-Sin Lin; Ann-Lii Cheng
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

4.  New LightCycler PCR for rapid and sensitive quantification of parvovirus B19 DNA guides therapeutic decision-making in relapsing infections.

Authors:  T C Harder; M Hufnagel; K Zahn; K Beutel; H J Schmitt; U Ullmann; P Rautenberg
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

5.  Evaluation of five commercial tests for detection of immunoglobulin M antibodies to human parvovirus B19.

Authors:  A L Bruu; S A Nordbø
Journal:  J Clin Microbiol       Date:  1995-05       Impact factor: 5.948

Review 6.  Parvovirus B19 infection.

Authors:  J R Kerr
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-01       Impact factor: 3.267

7.  Parvovirus B19 infection in pediatric transplant patients.

Authors:  B Nour; M Green; M Michaels; J Reyes; A Tzakis; J C Gartner; L McLoughlin; T E Starzl
Journal:  Transplantation       Date:  1993-10       Impact factor: 4.939

Review 8.  Human parvovirus B19.

Authors:  Erik D Heegaard; Kevin E Brown
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

9.  Parvovirus B19 outbreak on an adult ward.

Authors:  C Seng; P Watkins; D Morse; S P Barrett; M Zambon; N Andrews; M Atkins; S Hall; Y K Lau; B J Cohen
Journal:  Epidemiol Infect       Date:  1994-10       Impact factor: 2.451

10.  Different syndromes associated with B19 parvovirus viraemia in paediatric patients: report of four cases.

Authors:  M Zerbini; M Musiani; S Venturoli; G Gallinella; D Gibellini; G Gentilomi; M La Placa
Journal:  Eur J Pediatr       Date:  1992-11       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.